SAB Biotherapeutics To Present Phase 1 Data Demonstrating SAB-142's Multi-Specific Mechanism Of Action, Sustained Immunomodulation, Favorable Safety Profile Without Serum Sickness Or Anti-Drug Antibodies, And A Novel Pharmacokinetic Assay For Measuring The Drug

SAb Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that four oral presentations and two poster presentations have been accepted for presentation at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) being held November 5-8, 2025 in Montréal, Canada. Data highlights the progress of SAB BIO's lead program, SAB-142, which is in development for delaying the progression of T1D in new onset Stage 3 patients.

Key data to be presented includes:

• Data from the Phase 1 study showcasing the clinically validated, multi-specific mechanism of action with sustained immunomodulation of SAB-142.
• Safety data from the Phase 1 trial of SAB-142 demonstrating a favorable safety profile, characterized as not causing serum sickness or anti-drug antibodies at target dose.
• Details of the novel pharmacokinetic assay for measuring SAB-142.
• "We are making significant progress with the development of SAB-142, and the data we are sharing at this year's ISPAD annual conference adds to the supporting body of evidence for SAB-142 as a potential best-in-class therapy for the treatment of Stage 3 autoimmune type 1 diabetes," said presenting author Christoph Bausch, Chief Operating Officer, SAB BIO.